Research programme: chimeric antigen receptor T-cell therapeutics - Celyad

Drug Profile

Research programme: chimeric antigen receptor T-cell therapeutics - Celyad

Alternative Names: CAR NKp/B7H6; CAR-NKp30/B7H6; CAR-T B7H6; CAR-T NKG2Dß; CAR-T NKp30; CYAD-03; CYAD-04; CYAD-05; NKR-3 Allogeneic; NKR-3 Autologous; TCR-deficient NKR T-cell therapy - Celyad

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dartmouth College
  • Developer Celyad
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Oct 2018 Preclinical development for cancer is ongoing in Belgium (Celyad website, October 2018)
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral, Infusion)
  • 30 May 2017 Celyad has patent protection for allogeneic TCR-deficient CAR T-cells in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top